Neurofilament Light In Blood: From Discovery to Clinical Implementation

Discovery to Diagnostics Part 1



Neurological disorders affect hundreds of millions of people worldwide, both as a leading cause of death and as a long-term burden due to years of life with a disability(1). Despite differences in their causes, symptoms, treatments, and prognoses, they all involve neuronal injury. Identifying easily accessible biomarkers that can reflect various degrees of neuronal injury is important because they could be powerful tools for clinical research, drug development, diagnostics, and disease management. In the quest for such biomarkers, many researchers turned their attention to neurofilament light (NfL), a neuron-specific, axonal cytoskeleton protein released into the interstitial fluid and cerebrospinal fluid (CSF) upon neuronal injury and damage. NfL has emerged as a promising candidate for further investigation and potential application in this context. Download our whitepaper to learn more. 


1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X